NYSE:EBS Emergent BioSolutions (EBS) Stock Price, News & Analysis $7.93 +0.39 (+5.17%) (As of 07/5/2024 ET) Add Compare Share Share Today's Range$7.42▼$7.9750-Day Range$1.88▼$7.9452-Week Range$1.42▼$8.29Volume1.56 million shsAverage Volume2.18 million shsMarket Capitalization$415.53 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Emergent BioSolutions alerts: Email Address Emergent BioSolutions MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside0.9% Upside$8.00 Price TargetShort InterestBearish12.61% of Float Sold ShortDividend StrengthN/ASustainability-1.40Upright™ Environmental ScoreNews Sentiment0.32Based on 8 Articles This WeekInsider TradingSelling Shares$75,831 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.98) to ($1.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.55 out of 5 starsMedical Sector413th out of 879 stocksPharmaceutical Preparations Industry193rd out of 418 stocks 1.0 Analyst's Opinion Consensus RatingEmergent BioSolutions has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.Amount of Analyst CoverageEmergent BioSolutions has only been the subject of 1 research reports in the past 90 days.Read more about Emergent BioSolutions' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted12.61% of the float of Emergent BioSolutions has been sold short.Short Interest Ratio / Days to CoverEmergent BioSolutions has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Emergent BioSolutions has recently increased by 6.57%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEmergent BioSolutions does not currently pay a dividend.Dividend GrowthEmergent BioSolutions does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEmergent BioSolutions has received a 73.60% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Influenza vaccines", "Cholera vaccines", and "Antibiotics" products. See details.Environmental SustainabilityThe Environmental Impact score for Emergent BioSolutions is -1.40. Previous Next 1.8 News and Social Media Coverage News SentimentEmergent BioSolutions has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Emergent BioSolutions this week, compared to 2 articles on an average week.Search InterestOnly 20 people have searched for EBS on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Emergent BioSolutions insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $75,831.00 in company stock.Percentage Held by InsidersOnly 1.20% of the stock of Emergent BioSolutions is held by insiders.Percentage Held by Institutions78.40% of the stock of Emergent BioSolutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Emergent BioSolutions' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Emergent BioSolutions are expected to grow in the coming year, from ($1.98) to ($1.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Emergent BioSolutions is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Emergent BioSolutions is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEmergent BioSolutions has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Emergent BioSolutions' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Emergent BioSolutions Stock (NYSE:EBS)Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.Read More EBS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EBS Stock News HeadlinesJune 7, 2024 | insidertrades.comKathryn C. Zoon Sells 10,000 Shares of Emergent BioSolutions Inc. (NYSE:EBS) StockJuly 4 at 5:58 AM | americanbankingnews.comEmergent BioSolutions Inc. (NYSE:EBS) Short Interest Up 6.6% in JuneJuly 6, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. July 4 at 2:52 AM | americanbankingnews.comEmergent BioSolutions (NYSE:EBS) Stock Rating Reaffirmed by BenchmarkJuly 2, 2024 | benzinga.comWhy Is Vaccine Maker Emergent BioSolutions Stock Trading Higher On Tuesday?July 2, 2024 | globenewswire.comUpdate: Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure ProductsJuly 2, 2024 | globenewswire.comEmergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure ProductsJune 20, 2024 | globenewswire.comEmergent BioSolutions Announces Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 MillionJuly 6, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. June 6, 2024 | globenewswire.comEmergent BioSolutions Continues Driving Progress Against the Opioid Epidemic & Recognizes National Naloxone Awareness DayMay 21, 2024 | investorplace.com7 Stocks to Buy Immediately Following Strong EarningsMay 16, 2024 | investorplace.comVice Stock Vanguards: 3 Sin Stocks Delivering Heavenly ReturnsMay 10, 2024 | globenewswire.comEmergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 23, 2024May 2, 2024 | msn.comEmergent BioSolutions gains as results top estimates, co to cut 300 jobsMay 2, 2024 | msn.comEmergent BioSolutions Reports Blockbuster Q1 Results, Raises Guidance: What's Going On With The Stock?May 2, 2024 | bizjournals.comWhy this Gaithersburg biotech's stock is surgingMay 2, 2024 | finance.yahoo.comQ1 2024 Emergent BioSolutions Inc Earnings CallMay 2, 2024 | investorplace.comEmergent BioSolutions Layoffs 2024: What to Know About the Latest EBS Job CutsSee More Headlines Receive EBS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Emergent BioSolutions and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today7/06/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNYSE:EBS CUSIP29089Q10 CIK1367644 Webwww.emergentbiosolutions.com Phone(240) 631-3200Fax301-795-1899Employees1,600Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+0.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($11.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-760,500,000.00 Net Margins-47.68% Pretax Margin-47.12% Return on Equity-18.53% Return on Assets-7.14% Debt Debt-to-Equity Ratio0.67 Current Ratio1.08 Quick Ratio0.55 Sales & Book Value Annual Sales$1.05 billion Price / Sales0.40 Cash Flow$0.92 per share Price / Cash Flow8.58 Book Value$12.51 per share Price / Book0.63Miscellaneous Outstanding Shares52,400,000Free Float51,773,000Market Cap$415.79 million OptionableOptionable Beta1.62 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Richard S. Lindahl M.B.A. (Age 60)Executive VP, CFO & Treasurer Comp: $1.02MMs. Jennifer L. Fox (Age 51)Executive VP of External Affairs, General Counsel & Corporate Secretary Comp: $975.84kMs. Coleen Glessner (Age 53)Executive Vice President of Global Quality and Ethics & Compliance Comp: $959.37kMr. Paul A. Williams (Age 57)Senior Vice President of Products Business Comp: $846.97kMr. Joseph C. Papa Jr. (Age 68)CEO, President & Director Michelle PepinSenior VP & Chief Human Resource OfficerMs. Stephanie DuatschekSenior VP, Chief Strategy & Transformation OfficerDr. Kelly Lyn WarfieldSenior VP of Science & DevelopmentWilliam HartzelSenior Vice President of Manufacturing & BioservicesMore ExecutivesKey CompetitorsLigand PharmaceuticalsNASDAQ:LGNDDynavax TechnologiesNASDAQ:DVAXMannKindNASDAQ:MNKDBioCryst PharmaceuticalsNASDAQ:BCRXInnovivaNASDAQ:INVAView All CompetitorsInsiders & InstitutionsKathryn C ZoonSold 10,000 sharesTotal: $61,100.00 ($6.11/share)Kathryn C ZoonSold 1,830 sharesTotal: $8,436.30 ($4.61/share)Cetera Advisors LLCBought 169,317 shares on 5/24/2024Ownership: 0.323%Kathryn C ZoonSold 1,089 sharesTotal: $6,294.42 ($5.78/share)Tidal Investments LLCBought 13,352 shares on 5/17/2024Ownership: 0.025%View All Insider TransactionsView All Institutional Transactions EBS Stock Analysis - Frequently Asked Questions How have EBS shares performed this year? Emergent BioSolutions' stock was trading at $2.40 at the beginning of 2024. Since then, EBS shares have increased by 230.4% and is now trading at $7.93. View the best growth stocks for 2024 here. How were Emergent BioSolutions' earnings last quarter? Emergent BioSolutions Inc. (NYSE:EBS) posted its earnings results on Wednesday, May, 1st. The biopharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.65) by $4.24. The biopharmaceutical company earned $300.40 million during the quarter. Emergent BioSolutions had a negative trailing twelve-month return on equity of 18.53% and a negative net margin of 47.68%. What is Bob Kramer's approval rating as Emergent BioSolutions' CEO? 38 employees have rated Emergent BioSolutions Chief Executive Officer Bob Kramer on Glassdoor.com. Bob Kramer has an approval rating of 74% among the company's employees. How do I buy shares of Emergent BioSolutions? Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Emergent BioSolutions own? Based on aggregate information from My MarketBeat watchlists, some other companies that Emergent BioSolutions investors own include NVIDIA (NVDA), Salesforce (CRM), Novavax (NVAX), Advanced Micro Devices (AMD), Block (SQ), Netflix (NFLX) and Gilead Sciences (GILD). This page (NYSE:EBS) was last updated on 7/6/2024 by MarketBeat.com Staff From Our PartnersWhy Conservative Americans Are Turning to Gold in 2024Welcome to the financial rollercoaster of 2024, where inflation is relentless, stock markets are inflated, and...All American Assets | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored"The Biggest Drug Ever" Is ComingUBS bank predicts it will become "The Biggest Drug Ever." The Wall Street Journal believes it will be "Phar...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Emergent BioSolutions Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Emergent BioSolutions With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
